EPO grants second CRISPR patent to ERS Genomics

The European Patent Office (EPO) has granted a second CRISPR/Cas9 patent to a specialist genomics company, one month after revoking the Broad Institute of Harvard and MIT’s patent relating to the technology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

USPTO grants another CRISPR patent to Charpentier

12 March 2019 The US Patent and Trademark Office has issued a third CRISPR patent to inventor Emmanuelle Charpentier, one of the key figures in the CRISPR landscape.

Biotechnology

ERS Genomics signs CRISPR patent deal on industrial applications

16 October 2018 ERS Genomics, the company providing access to CRISPR/Cas9 IP owned by Emmanuelle Charpentier, has signed a licensing deal with synthetic biology startup Syngulon.

Americas

USPTO grants Charpentier-founded company first CRISPR patent

20 June 2018 The US Patent and Trademark Office has granted ERS Genomics its first US patent covering the use of CRISPR/Cas9 technology for gene editing.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

EPO grants second CRISPR patent to ERS Genomics

More on this story

Editor's picks

Editor's picks

More features